D1.1 Gap Analysis of Existing and Need for New Standards and Profiles
WP 01
D1.2 Requirements for a new ISO logical model
WP 01
D1.5 ISO IDMP Handbook
WP 02
D2.1 Endorsed Implementation Plan for Substance Management
WP 04
D4.1: Austria: Progress report on implementation
WP 04
D4.2 ESTONIA: Progress report on implementation
WP 04
D4.3 Finland: Progress report on refactoring or new build of national IT systems, migration of national data, and data interfaces to EMA’s SPOR
WP 04
D4.4: Germany: Progress report on implementation
WP 04
D4.5: Ireland: Progress report on Implementation
WP 04
D4.6: Norway: Progress report on implementation
WP 04
D4.7: SPAIN: Annual progress report on refactoring the national IT system, migration of national data and data interfaces to EMA´s SPOR
WP 04
D4.8: Sweden: Progress report on factoring or new build of national IT systems, migration of national data, and data interfaces to EMA’s SPOR
WP 04
D4.9: Belgium progress report on refactoring of the internal AFMPS Medicinal Product databases, alignment with SPOR, and provision of IDMP compatible data feed for national eHealth organisations
WP 04
D4.10 Croatia: Progress report on refactoring or new build of national IT systems, migration of national data, and data interfaces to EMA’s SPOR
WP 04
D4.11: Portugal: Progress report on implementation
WP 05
D5.1: Business requirements for the adoption of IDMP in eHealth Services
D8.1: Report on the link between IDMP and Pharmacotherapeutic Groups and the Need for Medical Data in Pharmacotherapeutic Audit (M22)
WP 08
D8.3: Protocol and Statistical Analysis Plan for Proof of Concept Studies
WP 08
D8.7: IDMP Coding Principles and Guidance for ICSRs
WP 10
D10.1: Assessment Framework Socio-Economic Impact
WP 10
D10.4: Review report of the GDPR and other legal requirements
WP 12
D12.2: Dissemination approach & communication strategy
WP 06
D6.2: Implement the smart substitution components for eDispensation
WP 01
D1.3 Report on education and certification programs
WP 01
D1.6 Demonstrator
WP 02
D2.2 Guidance document on how MPDs should map to substance data
WP 03
D3.1 Gap and requirements analysis
WP 04
D4.14 ISO IDMP medicinal product data for cross-border pilots
WP 04
D4.16 Best-practise ISO IDMP workshops
WP 04
D4.17 Gap Analysis of CTS
WP 05
D5.3 Guidelines for cross-border semantic interoperability
WP 05
D5.4 Semantic Specifications
WP 05
D5.5 Technical specifications for cross-border services
WP 05
D5.6 Guidelines to implement IDMP in National eHealth Services
WP 05
D5.7 Common minimum data set for implementation in the national NCA and eHealth solutions
WP 05
D5.8 Liaison with EC MSs and stakeholders
WP 06
D6.1 UNICOM IDMP Data Base
WP 06
D6.3 Redesign and implementation of an enhanced IDMP compliant User Portal system and of an IDMP extended CDA display tool
WP 06
D6.4 eHDSI semantic components enhancements for IDMP
WP 07
D7.2 Proof of Concept demonstrator report
WP 08
D8.9 Procedures for use of IDMP in Personalised Medicine
WP 09
D9.1 An analysis of the IDMP medicinal product identification data provided by NCAs (and SPOR) compared to that needed in MPD for clinical care and for secondary uses
WP 09
D9.2 Implementation Guidance for Identification of Medicinal Products (IDMP) in Medicinal Product Dictionaries
WP 09
D9.4 IDMP Implementation guidance for pharmacy system suppliers (focus on patient medication list)
WP 10
D10.2 Interim report on cost benefit data collection